← Stock Trading Canary · All insider profiles
INSIDER PROFILE · UK
Sapna Shah
Director of BioPharma Credit PLC | Non-Executive Director | PDMR - Non Executive Director | PDMR - Non-Executive Director
Profile key: uk|sapna shah
Purchase history
- Companies traded
- 3
- Purchases · 12M
- 4
- Purchases · 24M
- 11
- Average purchase
- £25,155
- Gross purchase value
- £276,710
- Last purchase
- 2026-07-17
- Completed 20D events
- 8.0
- Outcome status
- PASS
Latest company: Supermarket Income REIT PLC
Companies: BioPharma Credit PLC | Pantheon Infrastructure PLC | Supermarket Income REIT PLC
Post-purchase outcomes
Benchmark-relative outcomes are available against FTSE 100.
- Excess return = stock return − FTSE 100 return over the same period.
- Hit rate = positive excess-return events ÷ completed events.
- Price coverage = valid point-in-time prices ÷ events mature enough for that period.
- Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 8Developing | 100.0% (8/8) | 25.0% (2/8) | -1.7% | -1.6% | -4.1% |
| 20D | 8Developing | 100.0% (8/8) | 12.5% (1/8) | -3.4% | -3.7% | -8.8% |
| 60D | 8Developing | 100.0% (8/8) | 37.5% (3/8) | -0.4% | -0.7% | -9.0% |
| 120D | 7Developing | 100.0% (7/7) | 28.6% (2/7) | -3.9% | -0.7% | -6.6% |
Research patterns
- First purchase in 12M
- 1/5
- Large purchase ≥ €100k
- 0/8
- Cluster buying · 15D
- 5/8
- Buying the dip · ≥20% below prior 52W high
- 1/8
- Routine / opportunistic
- Not classifiable
Counts are profile-wide, point-in-time research labels. They never affect the insider score or ranking.
Every completed outcome is shown; n<5 is descriptive small-sample evidence and is not scored. Disclosure-level observations published on the same date may share a return path and may not be statistically independent. These results never affect the insider score or ranking.